1133 related articles for article (PubMed ID: 29370992)
21. Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.
Zhou M; Bui N; Bolleddu S; Lohman M; Becker HC; Ganjoo K
Immunotherapy; 2020 Dec; 12(18):1303-1312. PubMed ID: 32967520
[No Abstract] [Full Text] [Related]
22. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
23. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
24. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract][Full Text] [Related]
25. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
[TBL] [Abstract][Full Text] [Related]
26. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P; Siefker-Radtke A; de Braud F; Basso U; Calvo E; Bono P; Morse MA; Ascierto PA; Lopez-Martin J; Brossart P; Rohrberg K; Mellado B; Fischer BS; Meadows-Shropshire S; Abdel Saci ; Callahan MK; Rosenberg J
J Clin Oncol; 2019 Jul; 37(19):1608-1616. PubMed ID: 31100038
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Postow MA; Chesney J; Pavlick AC; Robert C; Grossmann K; McDermott D; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor D; Salama AK; Taylor M; Ott PA; Rollin LM; Horak C; Gagnier P; Wolchok JD; Hodi FS
N Engl J Med; 2015 May; 372(21):2006-17. PubMed ID: 25891304
[TBL] [Abstract][Full Text] [Related]
32. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Cowey CL; Lao CD; Schadendorf D; Dummer R; Smylie M; Rutkowski P; Ferrucci PF; Hill A; Wagstaff J; Carlino MS; Haanen JB; Maio M; Marquez-Rodas I; McArthur GA; Ascierto PA; Long GV; Callahan MK; Postow MA; Grossmann K; Sznol M; Dreno B; Bastholt L; Yang A; Rollin LM; Horak C; Hodi FS; Wolchok JD
N Engl J Med; 2015 Jul; 373(1):23-34. PubMed ID: 26027431
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
[TBL] [Abstract][Full Text] [Related]
35. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC; Ugurel S; Leiter U; Meier F; Gutzmer R; Haferkamp S; Zimmer L; Livingstone E; Eigentler TK; Hauschild A; Kiecker F; Hassel JC; Mohr P; Fluck M; Thomas I; Garzarolli M; Grimmelmann I; Drexler K; Spillner AN; Eckhardt S; Schadendorf D;
Lancet; 2023 Sep; 402(10404):798-808. PubMed ID: 37451295
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
38. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
39. Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.
Hogg D; Monzon JG; Ernst S; Song X; McWhirter E; Savage KJ; Skinn B; Romeyer F; Smylie M
Curr Oncol; 2020 Aug; 27(4):204-214. PubMed ID: 32905202
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY; Chevret S; Le Cesne A; Brahmi M; Penel N; Cousin S; Bertucci F; Bompas E; Ryckewaert T; Soibinet P; Boudou-Rouquette P; Saada Bouzid E; Soulie P; Valentin T; Lotz JP; Tosi D; Neviere Z; Cancel M; Ray-Coquard I; Gambotti L; Legrand F; Lamrani-Ghaouti A; Simon C; Even C; Massard C
Lancet Oncol; 2023 Aug; 24(8):892-902. PubMed ID: 37429302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
